Conversely, the use of GLP-1 agonists is not recommended in lean patients with PCOS, so as additional weight loss may additionally block hypthalamo–hypophyseal axis, which then may presents a major challenge both for diagnosis and further treatment [32]. Here, GCG is linked to polycystic ovary syndrome.